Department of Rehabilitation Medicine, Amsterdam University Medical Centers, Location Vrije Universiteit, Amsterdam, the Netherlands.
Amsterdam Movement Sciences, Rehabilitation & Development, Amsterdam, The Netherlands.
Neuropediatrics. 2024 Oct;55(5):294-302. doi: 10.1055/s-0044-1787103. Epub 2024 May 22.
Spasticity and dystonia are movement impairments that can occur in childhood-onset neurological disorders. Severely affected individuals can be treated with intrathecal baclofen (ITB). Concomitant use of ITB and opioids has been associated with central nervous system (CNS) depression. This study aims to describe the clinical management of this interaction, based on a case series and review of literature.
Four individuals with childhood-onset CNS disorders (age 8-24) and CNS-depressant overdose symptoms after the concomitant use of ITB and opioids are described. The Drug Interaction Probability Scale (DIPS) was calculated to assess the cause-relationship (doubtful <2, possible 2-4, probable 5-8, and highly probable >8) of the potential drug-drug interaction. A literature review of similar previously reported cases and the possible pharmacological mechanisms of opioid-baclofen interaction is provided.
After ITB and opioid co-administration, three out of four patients had decreased consciousness, and three developed respiratory depression. DIPS scores indicated a possible cause-relationship in one patient (DIPS: 4) and a probable cause-relationship in the others (DIPS: 6, 6, and 8). Discontinuation or adjusting ITB or opioid dosages resulted in clinical recovery. All patients recovered completely. In the literature, two articles describing nine unique cases were found.
Although the opioid-ITB interaction is incompletely understood, concomitant use may enhance the risk of symptoms of CNS-depressant overdose, which are potentially life-threatening. If concomitant use is desirable, we strongly recommend to closely monitor these patients to detect interaction symptoms early. Awareness and monitoring of the potential opioid-ITB interaction is essential to reduce the risk of severe complications.
痉挛和肌张力障碍是儿童期起病的神经障碍中出现的运动障碍。严重受影响的个体可以接受鞘内巴氯芬(ITB)治疗。同时使用 ITB 和阿片类药物与中枢神经系统(CNS)抑制有关。本研究旨在基于病例系列和文献复习描述这种相互作用的临床管理。
描述了 4 名患有儿童期起病的中枢神经系统疾病(年龄 8-24 岁)的个体,他们在同时使用 ITB 和阿片类药物后出现 CNS 抑制剂过量的症状。使用药物相互作用可能性量表(DIPS)来评估潜在药物相互作用的因果关系(可疑<2、可能 2-4、很可能 5-8 和极可能>8)。对类似的先前报告病例进行文献复习,并提供阿片类药物-巴氯芬相互作用的可能药理学机制。
在 ITB 和阿片类药物共同给药后,4 名患者中有 3 名出现意识降低,3 名出现呼吸抑制。DIPS 评分表明 1 名患者(DIPS:4)存在可能的因果关系,其他 3 名患者(DIPS:6、6 和 8)存在很可能的因果关系。停用或调整 ITB 或阿片类药物剂量可导致临床恢复。所有患者均完全恢复。在文献中,发现了两篇描述 9 个独特病例的文章。
尽管阿片类药物-ITB 相互作用尚未完全了解,但同时使用可能会增加 CNS 抑制剂过量症状的风险,这些症状可能危及生命。如果需要同时使用,我们强烈建议密切监测这些患者以早期发现相互作用症状。了解并监测潜在的阿片类药物-ITB 相互作用对于降低严重并发症的风险至关重要。